TLSI
TriSalus Life Sciences Inc.NASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$261.63M
P/E Ratio
—
EPS
$-1.84
Beta
0.54
52W High
$7.95
52W Low
$3.42
50-Day MA
$4.42
200-Day MA
$5.00
Dividend Yield
—
Profit Margin
-86.90%
Forward P/E
—
PEG Ratio
—
About TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company at the forefront of transforming cancer therapy through its proprietary localized drug delivery systems. By optimizing the efficacy of immuno-oncology agents and tackling significant distribution hurdles within the tumor microenvironment, TriSalus aims to enhance therapeutic outcomes for cancer patients. The company boasts a compelling pipeline of clinical programs that underscore its dedication to addressing the pressing need for advanced cancer treatments. With a strategic vision centered on expanding access to these critical therapies, TriSalus is positioned to be a significant player in the evolving oncology sector.
Fundamentals
| Revenue (TTM) | $45.15M |
| Gross Profit (TTM) | $38.19M |
| EBITDA | $-26.32M |
| Operating Margin | -24.80% |
| Return on Equity | -496.20% |
| Return on Assets | -56.80% |
| Revenue/Share (TTM) | $1.19 |
| Book Value | $-0.68 |
| Price-to-Book | 30.29 |
| Price-to-Sales (TTM) | 5.79 |
| EV/Revenue | 6.1 |
| EV/EBITDA | -5.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 59.80% |
| Shares Outstanding | $61.41M |
| Float | $51.51M |
| % Insiders | 28.21% |
| % Institutions | 21.03% |
Historical Volatility
HV 10-Day
38.49%
HV 20-Day
42.76%
HV 30-Day
46.55%
HV 60-Day
63.73%
HV Rank
12.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($9.20 target)
1
Strong Buy4
BuyData last updated: 4/30/2026